Progyny Inc Stock Shows Oversold Signal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy PGNY?
Source: NASDAQ.COM
- Oversold Indicator: Progyny Inc (Ticker: PGNY) hit an RSI of 29.9 during Monday's trading, indicating an oversold condition as shares dipped to $17.77, suggesting that recent heavy selling may be nearing exhaustion, prompting investors to consider buying opportunities.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 36.7, PGNY's 29.9 RSI reflects relative weakness, potentially attracting investors looking for rebounds and increasing market participation.
- Historical Performance: PGNY's 52-week low stands at $16.755 and the high at $28.75, with the current trading price at $17.75, indicating potential rebound space within its volatility range, which may attract short-term traders.
- Investor Sentiment: As PGNY approaches its 52-week low, investor sentiment may shift to optimism, especially in light of the oversold signal, potentially encouraging more investors to seek entry points to capture potential rebounds.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PGNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PGNY
Wall Street analysts forecast PGNY stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 18.250
Low
26.00
Averages
29.75
High
34.00
Current: 18.250
Low
26.00
Averages
29.75
High
34.00
About PGNY
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Progyny Inc Stock Shows Oversold Signal
- Oversold Indicator: Progyny Inc (Ticker: PGNY) hit an RSI of 29.9 during Monday's trading, indicating an oversold condition as shares dipped to $17.77, suggesting that recent heavy selling may be nearing exhaustion, prompting investors to consider buying opportunities.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 36.7, PGNY's 29.9 RSI reflects relative weakness, potentially attracting investors looking for rebounds and increasing market participation.
- Historical Performance: PGNY's 52-week low stands at $16.755 and the high at $28.75, with the current trading price at $17.75, indicating potential rebound space within its volatility range, which may attract short-term traders.
- Investor Sentiment: As PGNY approaches its 52-week low, investor sentiment may shift to optimism, especially in light of the oversold signal, potentially encouraging more investors to seek entry points to capture potential rebounds.
See More
Progyny Leadership to Participate in Investor Conferences
- Investor Conference Schedule: Progyny's leadership team will participate in several investor conferences in March, including Leerink Partners, Barclays, and KeyBanc, showcasing the company's leadership in women's health and family building solutions.
- Executive Participation: CFO Mark Livingston will engage in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, while CEO Pete Anevski will participate in a fireside chat at the Barclays Global Healthcare Conference on March 11, enhancing the company's visibility.
- Technology Discussion: COO Melissa Cummings will join a panel discussion on fertility technology and women's health at the KeyBanc Capital Markets Healthcare Forum on March 17, highlighting Progyny's expertise and innovation in the field.
- Live Streaming: Live audiocasts and replays of all fireside chats will be available in the Events and Presentations section of Progyny's investor relations website, ensuring investors can stay updated on the company's latest developments.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Progyny Reports Record Revenue and EBITDA for 2025
- Record Financial Performance: Progyny achieved $1.29 billion in revenue and $222 million in adjusted EBITDA for 2025, exceeding the midpoint of original guidance by nearly $90 million and $28 million respectively, showcasing the company's robust market performance and profitability.
- Strong Cash Flow Growth: The operating cash flow reached a record $210 million in 2025, reflecting a 17% increase over 2024, which provides strong support for future investments and shareholder returns, further solidifying the company's financial health.
- Near 100% Client Retention: Progyny reported nearly 100% client retention among large employers, with 30% of clients expanding benefits for 2026, indicating sustained competitiveness and high customer satisfaction in the market.
- New Product Strategic Launch: The introduction of Progyny Select targets the needs of 50 million smaller employers, expected to contribute new revenue streams in 2027, marking a strategic shift in the company's focus and further expanding its market share.
See More
Progyny Releases 2026 Financial Outlook with Strong Q4 Results
- Earnings Beat: Progyny reported a Q4 non-GAAP EPS of $0.48, exceeding expectations by $0.08, with revenue of $318.4 million reflecting a 6.7% year-over-year increase, surpassing estimates by $4.14 million, indicating strong market performance.
- 2026 Outlook: The company projects 2026 revenue between $1.355 billion and $1.405 billion, representing growth of 5.1% to 9.0%; excluding $48.5 million from a large client in 2025, expected growth rises to 9.3% to 13.3%, showcasing optimism for future performance.
- Net Income Projections: Net income for 2026 is anticipated to be between $95.4 million and $106.1 million, translating to diluted EPS of $1.10 to $1.22 based on approximately 87 million shares, reflecting sustained profitability improvements.
- Adjusted EBITDA Forecast: Adjusted EBITDA is projected to range from $224 million to $239 million, with adjusted EPS expected between $1.83 and $1.95, highlighting effective cost management and profitability enhancement strategies.
See More
Progyny (PGNY) to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Progyny (PGNY) is set to announce its Q4 2023 earnings on February 26 after market close, with a consensus EPS estimate of $0.40, reflecting a 4.8% year-over-year decline, which may impact investor sentiment.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $314.26 million, representing a 5.3% year-over-year increase, indicating the company's ongoing growth potential in the fertility health sector despite the slight EPS decline.
- Historical Performance: Over the past two years, Progyny has exceeded EPS estimates 100% of the time and revenue estimates 50% of the time, demonstrating the company's stability and reliability in financial performance.
- Revision Trends: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments, and revenue estimates have also experienced two upward revisions, reflecting analysts' optimistic outlook on the company's future performance.
See More
Progyny Inc Stock Shows Oversold Signal
- Oversold Indicator: Progyny Inc (Ticker: PGNY) hit an RSI of 29.9 during Monday's trading, indicating an oversold condition as shares dipped to $17.77, suggesting that recent heavy selling may be nearing exhaustion, prompting investors to consider buying opportunities.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 36.7, PGNY's 29.9 RSI reflects relative weakness, potentially attracting investors looking for rebounds and increasing market participation.
- Historical Performance: PGNY's 52-week low stands at $16.755 and the high at $28.75, with the current trading price at $17.75, indicating potential rebound space within its volatility range, which may attract short-term traders.
- Investor Sentiment: As PGNY approaches its 52-week low, investor sentiment may shift to optimism, especially in light of the oversold signal, potentially encouraging more investors to seek entry points to capture potential rebounds.
See More
Progyny Leadership to Participate in Investor Conferences
- Investor Conference Schedule: Progyny's leadership team will participate in several investor conferences in March, including Leerink Partners, Barclays, and KeyBanc, showcasing the company's leadership in women's health and family building solutions.
- Executive Participation: CFO Mark Livingston will engage in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, while CEO Pete Anevski will participate in a fireside chat at the Barclays Global Healthcare Conference on March 11, enhancing the company's visibility.
- Technology Discussion: COO Melissa Cummings will join a panel discussion on fertility technology and women's health at the KeyBanc Capital Markets Healthcare Forum on March 17, highlighting Progyny's expertise and innovation in the field.
- Live Streaming: Live audiocasts and replays of all fireside chats will be available in the Events and Presentations section of Progyny's investor relations website, ensuring investors can stay updated on the company's latest developments.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Progyny Reports Record Revenue and EBITDA for 2025
- Record Financial Performance: Progyny achieved $1.29 billion in revenue and $222 million in adjusted EBITDA for 2025, exceeding the midpoint of original guidance by nearly $90 million and $28 million respectively, showcasing the company's robust market performance and profitability.
- Strong Cash Flow Growth: The operating cash flow reached a record $210 million in 2025, reflecting a 17% increase over 2024, which provides strong support for future investments and shareholder returns, further solidifying the company's financial health.
- Near 100% Client Retention: Progyny reported nearly 100% client retention among large employers, with 30% of clients expanding benefits for 2026, indicating sustained competitiveness and high customer satisfaction in the market.
- New Product Strategic Launch: The introduction of Progyny Select targets the needs of 50 million smaller employers, expected to contribute new revenue streams in 2027, marking a strategic shift in the company's focus and further expanding its market share.
See More
Progyny Releases 2026 Financial Outlook with Strong Q4 Results
- Earnings Beat: Progyny reported a Q4 non-GAAP EPS of $0.48, exceeding expectations by $0.08, with revenue of $318.4 million reflecting a 6.7% year-over-year increase, surpassing estimates by $4.14 million, indicating strong market performance.
- 2026 Outlook: The company projects 2026 revenue between $1.355 billion and $1.405 billion, representing growth of 5.1% to 9.0%; excluding $48.5 million from a large client in 2025, expected growth rises to 9.3% to 13.3%, showcasing optimism for future performance.
- Net Income Projections: Net income for 2026 is anticipated to be between $95.4 million and $106.1 million, translating to diluted EPS of $1.10 to $1.22 based on approximately 87 million shares, reflecting sustained profitability improvements.
- Adjusted EBITDA Forecast: Adjusted EBITDA is projected to range from $224 million to $239 million, with adjusted EPS expected between $1.83 and $1.95, highlighting effective cost management and profitability enhancement strategies.
See More
Progyny (PGNY) to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Progyny (PGNY) is set to announce its Q4 2023 earnings on February 26 after market close, with a consensus EPS estimate of $0.40, reflecting a 4.8% year-over-year decline, which may impact investor sentiment.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $314.26 million, representing a 5.3% year-over-year increase, indicating the company's ongoing growth potential in the fertility health sector despite the slight EPS decline.
- Historical Performance: Over the past two years, Progyny has exceeded EPS estimates 100% of the time and revenue estimates 50% of the time, demonstrating the company's stability and reliability in financial performance.
- Revision Trends: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments, and revenue estimates have also experienced two upward revisions, reflecting analysts' optimistic outlook on the company's future performance.
See More
